Sanofi's sleeping sickness drug cures 95% of people in
phase 2/3 trial, boosting plan to stop transmission
By Nick Paul Taylor
Sanofi’s oral sleeping
sickness candidate acoziborole has achieved 95% efficacy in a late-phase
clinical trial, delivering a boost to a global push to interrupt transmission
of the parasitic disease by 2030.
No comments:
Post a Comment